Serum apolipoprotein e level is not increased in Alzheimer's disease: The Rotterdam study
Neuroscience Letters , Volume 248 - Issue 1 p. 21- 24
The APOE*4 allele of the apolipoprotein E gene (APOE) is an important risk factor for Alzheimer's disease. It has been suggested that levels of apolipoprotein E (apoE) in plasma are increased in Alzheimer's disease. In this population-based study, we found that serum apoE levels were lower in Alzheimer patients compared to non-demented controls (0.75 μmol/l (SD 0.35), vs. 0.83 μmol/l (SD 0.40), P < 0.05). This finding is in accordance with lower serum apoE levels as observed in carriers of the APOE*4 allele, who are over-represented in Alzheimer's disease. After adjustment for age, sex, total protein, albumin level, body mass index and the APOE genotype, the difference in serum apoE levels largely disappeared. Our population-based study suggests that the differences in serum apoE level between Alzheimer patients and controls are mainly the result of differences in the distribution of the APOE genotype.
|Alzheimer's disease, Apolipoprotein E, Atherosclerosis, Dementia, Plasma, Serum level|
|Organisation||Erasmus MC: University Medical Center Rotterdam|
Slooter, A.J.C, de Knijff, P, Hofman, A, Cruts, M, Breteler, M.M.B, van Broeckhoven, C, … van Duijn, C.M. (1998). Serum apolipoprotein e level is not increased in Alzheimer's disease: The Rotterdam study. Neuroscience Letters, 248(1), 21–24. doi:10.1016/S0304-3940(98)00339-5